All Episodes
Displaying 1 - 30 of 32 in total
A Capital Markets Outlook for 2025: 2024, A Year in Review
In this DNB//Back Bay Healthcare Capital Markets podcast episode, Jim Cirenza, Head of Fixed Income and Equities at DNB, Kristoffer Braaten, Director and Head of Equit...
The Optimism of Bispecific Antibodies
The topic of bispecific antibodies has been an area of interest in the pharma space for a long time now. The recent news of the notable late-stage data from Akeso and ...
Dynamics in Healthcare Focused Markets
In this DNB//Back Bay Healthcare Capital Markets Episode, Vasilios Kofitsas, Partner and Managing Director at Back Bay Life Science Advisors speaks with Jim Cirenza an...
From NASH to MASH: Current Market Dynamics in Hepatology
After a summer away from podcasting, Back Bay Life Science Advisors’ Dr. Pete Bak and Christian Thienel are back on the mic to discuss current market dynamics in liver...
Key Considerations for a US Healthcare IPO
In this DNB//Back Bay Healthcare Capital Markets podcast episode, learn about the key considerations, mechanics and timelines of going public on a US exchange. Topics...
Drug Development in Obesity
Guests: Pete Bak and Christian Thienel Length: 27 minutes In this episode of The Life Science Report, Dr. Pete Bak and Back Bay Director, Christian Thienel catch up on...
The Current Dynamics in Capital Markets
Welcome to another episode with the DNB//Back Bay Partnership for Healthcare.In this episode Jonathan Gertler, Back Bay CEO and Managing Partner, is once again joined ...
Vaccine Developments 2024: A Podcast Discussion on Latest Vaccine Technology and Ongoing Clinical Developments
Guests: Pete Bak and Christian Thienel Length: 37 minutes With the advent of COVID-19 in 2020 and 2021, we saw a tremendous amount of interest in not only COVID vaccin...
Trends and Investment Activity in Radiopharmaceuticals and Psychedelics
A Podcast Discussion on the Trends and Investment Activity in Radiopharmaceuticals and PsychedelicsGuests: Pete Bak and Christian ThienelLength: 25 minutesHere at Back...
Vertex’s Exa-cel to Biogen and Sage’s Zurzuvae: Notable Product Approvals of 2023
As we move into 2024, Back Bay’s strategic advisors summarize key product approvals from three classes and indications over this past year, including the December CRIS...
Monthly Roundup of News from Healthcare Development
In our latest podcast, Back Bay Life Science Advisors focused on the chronic and rare disease development of kidney disease. Recently, there have been some changes in ...
The Current and Future Landscape of Healthcare IPO Markets
With the DNB//Back Bay Partnership for HealthcareIn the current markets, Healthcare continues to rally as the second-largest industry behind technology in the stock ma...
The Heart of the Matter: Behind the Renewed Interest in Cardiovascular Disease
A conversation on the rising trends in the cardiology spaceCardiology has historically been a cornerstone of large pharmaceutical portfolios. The late 2000s and 2010s ...
The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates
In this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this year, “The Transact...
Investing in Health Tech & Digital Medicine: Expert Talk with Mikaela Odlander & Edward Kliphuis
The world of health tech has changed dramatically since decades ago when physicians had to endure 11 keystrokes to prescribe a single aspirin. These days, AI-based rad...
Contingencies for Biopharma, Medtech Deal Planning in a Down Market
For biopharma and medtech companies developing new treatments, capital for advancement and growth is invariably dependent on strategic preparation, differentiation, an...
Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022
In our first podcast episode of 2023, Back Bay’s strategic advisors summarize some of the most compelling healthcare development stories from 2022.
Preparing BioPharma and Medtech Companies for Public Listing - Back Bay Life Science Advisors and Nasdaq Nordic
The Nordic Nasdaq system—specifically the Stockholm markets—recently unveiled access to US biopharma and medtech companies to list on the Stockholm Exchange, either pr...
The Promising Field of Targeted Protein Degraders (TPDs)
Dr. Mavra Nasir recently published a thought piece in Biopharma Dealmakers outlining the current state of play in the promising field of protein degradation. In this e...
Early Market Access and Pricing with Pete Bak, Christian Thieniel and Brendan Wang
Christian Thieniel and Brendan Wang, two senior members of the Back Bay Life Science Advisors team, offer guidance on issues related to pricing and early market access.
Living Medicines – Current and Future Uses of Car T Cells with Peter Bak, PhD and Mike Bogetofte Barnkob, MD, PhD
In this episode of Back Bay’s industry podcast, The Life Science Report, Dr. Peter Bak is joined by Mike Bogetofte Barnkob, a doctor with the Department of Clinical Im...
The Evolving Regulatory Framework for Novel Medicines in the EU
with Peter Bak and Alexander Natz Biopharma companies looking to establish a footprint in Europe face country-specific decision-making processes. The health technol...
The Commercial Potential of Optogenetic Therapies
The Commercial Potential of Optogenetic Therapies with Peter Bak, PhD and Kevin Norman, PhD
The Latest on Antibiotic Development, Back Bay Life Science Advisors with Antabio
The Latest on Antibiotic Development, Back Bay Life Science Advisors with Antabio with Peter Bak, PhD, Back Bay Life Science Advisors and Marc Lemonnier, Antabio
Best Practices for Successful Sell-Side Licensing, Partnering and M&A
Best Practices for Successful Sell-Side Licensing, Partnering and M&A with Stephan Gauldie, PhD, Gregory Benning and Jonathan P. Gertler, MD, Back Bay Life Science Ad...
Cell and Gene Therapy Investment Trends
Cell and Gene Therapy Investment Trends with Pete Bak, PhD Kyle O’Neil and Brendan Wang Cell and gene therapies are currently among the hottest investments in the b...
MedTech Investing with Paul LaViolette of SV Health Investors and Jonathan P. Gertler, MD, Back Bay Life Science Advisors and BioVentures Medtech Funds
Join the conversation between Paul LaViolette, SV Health Investors and Jonathan P. Gertler, MD, Back Bay Life Science Advisors and BioVentures Medtech Funds For yea...
Remote Patient Monitoring
One of the unexpected outcomes of the COVID-19 pandemic has been the rapid and widespread uptake of remote patient monitoring. As with vaccines, much groundwork had be...
New Drug Pricing and Market Access
In this episode of our life science industry podcast, Dr. Peter Bak sits down with Brendan Wang and Christian Thienel of Back Bay Life Science Advisors to discuss how ...
The Question of Investment in Antimicrobials
In this episode Jonathan Gertler, Back Bay’s CEO and Managing Partner, sits down with Dr. Peter Bak, Managing Director at Back Bay, to discuss Dr. Bak’s latest article...